Oct 2026· Prostate Cancer and Prostatic Diseases· 0 citations· 69 references
Medicine
TL;DR
Organized, risk-adapted pathways integrating PSA, MRI, biomarkers, and baseline risk may better preserve early-detection benefits while reducing overdiagnosis and inequity.
Abstract
Background
Prostate cancer epidemiology is evolving because of three simultaneous factors: a rising global burden, population aging, and renewed debate about how early detection can reduce advanced disease without returning to non-risk-adapted PSA testing. This Review provides an updated overview of prostate cancer incidence, mortality, prevalence, risk factors, disparities, and screening implications.
Methods
We synthesized recent systematic reviews, meta-analyses, randomized screening trials, and population-based registry data, supplemented by landmark historical studies.
Results
Current trends cannot be interpreted without accounting for screening policy, diagnostic intensity, access to MRI and biomarkers, inherited susceptibility, and health-system capacity. Age, family history, ancestry, and germline risk remain the strongest determinants. Most modifiable exposures are weaker and inconsistent, and are better framed within cardiometabolic health and survivorship care. Organized, risk-adapted pathways integrating PSA, MRI, biomarkers, and baseline risk may better preserve early-detection benefits while reducing overdiagnosis and inequity.
Conclusions
Progress will depend on preventing metastatic disease, minimizing overtreatment, and implementing modern diagnostics equitably.
Although overall colorectal cancer (CRC) incidence and mortality have declined with widespread screening, early-onset CRC (EOCRC), defined as diagnosis before age 50, continues to rise. EOCRC partially differs from late-onset CRC (LOCRC) in clinical presentation, molecular features, polyp characteristics, and patterns...
Vanessa Lu, Fiona Xu, G. Graziosi et al.· Gastroenterology Insights· 0 citations
Early-onset colorectal cancer (EOCRC), defined as colorectal cancer diagnosed before age 50, has become an increasing global public health concern. Incidence rates have risen among younger adults in many countries, despite stable or declining rates in older populations. This review examines global EOCRC epidemiology, p...
Kacper Wrzosek, Agata Koba, Pola Bakalczuk et al.· Cancers· 0 citations
The priority for translation is not maximal technological integration, but selective use of additional information when it provides actionable incremental benefit while preserving the accessibility, effectiveness, and public-health strengths of organized screening.
S. Luncă, S. Morarasu, G. Dimofte· Medicina· 0 citations
This review synthesizes current advances in CRC epidemiology, risk factors, signaling biology, clinical presentation, screening, diagnosis, and management across the care continuum, and frames CRC as a systems‐level disease in which genomic instability, epigenetic dysregulation, metabolic remodeling, tumor microenviron...
Kai-Rui Wan, Ke Tang, Ling-Long Wang et al.· MedComm· 0 citations
How blood and urine tests, alongside genetic risk information, can help identify the men most likely to harbor aggressive prostate cancer-enabling early detection and intervention while avoiding unnecessary biopsies and potential harm in men at low risk is discussed.
J. Stangl-Kremser, S. Salami· European Urology Focus· 0 citations
CONTEXT
There are substantial regional differences in prostate cancer (PCa) epidemiology reflecting differences in risk factors, screening, management, and access to care.
OBJECTIVE
To assess geographical differences and temporal trends in PCa incidence and mortality and PCa risk factors.
EVIDENCE ACQUISITION
Estim...
G. Gandaglia, A. Weiner, A. Briganti et al.· European Urology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.